Skip to content
World Today News
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Technology
  • World
World Today News
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Technology
  • World
Friday, December 5, 2025
World Today News
World Today News
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Technology
  • World
Copyright 2021 - All Right Reserved
Home » RSBI:REGULATORY-OVERSIGHT » Page 2
Tag:

RSBI:REGULATORY-OVERSIGHT

Technology

Blockchain Global Director Banned from Australia Over Cryptocurrency Exchange

by Rachel Kim – Technology Editor October 29, 2025
written by Rachel Kim – Technology Editor

Australia Blocks Blockchain Global Director From Departing the Country

Sydney – Australian authorities have‌ prevented Blockchain⁤ Global ⁤director Peter⁤ Hodgson from leaving ⁢the​ country, escalating scrutiny ‌of the cryptocurrency firm amid ongoing investigations ⁤into its operations‌ and financial dealings. Hodgson was stopped​ at sydney Airport on Tuesday, with border officials acting on a court order, according to a statement from the⁣ Australian Federal Police (AFP).

The move ‌signals⁣ a deepening probe​ into Blockchain Global, a once-prominent ​player ‌in Australia’s cryptocurrency landscape, which⁢ collapsed into voluntary management in February 2023 ⁣owing creditors⁢ approximately AUD $140 million (USD‌ $91‌ million). The AFP’s actions are aimed at preserving assets and ensuring ⁤Hodgson’s availability for further questioning related to potential⁢ breaches ⁣of corporate ‌law and possible insolvency offenses. This case highlights ⁢the increasing ‌regulatory pressure on the cryptocurrency sector ‌in Australia and the potential consequences for company ⁢directors facing financial scrutiny.

Hodgson’s travel ban stems from‍ an examination into allegations of improper transfer of funds ⁣and potential mismanagement within Blockchain Global. The AFP executed search warrants at several properties linked to‍ Hodgson and the company in March,⁣ seizing ⁢documents and electronic devices. Authorities are focusing on transactions involving the company’s digital⁢ asset holdings and its Australian Cryptocurrency‍ exchange (ACX) platform.

“The AFP is committed ⁢to investigating allegations of financial crime​ and holding individuals accountable for their actions,” ‍a spokesperson for the AFP stated. “This includes ensuring that ‌those involved in the administration⁣ of companies comply with their legal obligations.”

Blockchain global’s administrators,Jirsch Sutherland,are continuing to investigate the⁣ company’s ‌financial affairs and are working to recover assets for ‌creditors. The administrators have ⁣previously‌ expressed concerns about the lack ⁤of transparency surrounding certain transactions and the difficulty in tracing the company’s digital‌ assets.

The Australian Securities and Investments Commission (ASIC) ​is ‍also​ involved in the investigation, focusing on potential breaches of director’s duties. The case is ‌being closely‍ watched by industry observers, who beleive it could set a precedent for future enforcement actions against ‌cryptocurrency companies and their executives in Australia.‍ Hodgson has not yet‌ publicly ‍commented on the travel ban ⁤or the⁢ allegations against him.

October 29, 2025 0 comments
0 FacebookTwitterPinterestEmail
Health

Title: Alkermes Acquires Avadel for $2.1 Billion, Expanding into Sleep Medicine

by Dr. Michael Lee – Health Editor October 22, 2025
written by Dr. Michael Lee – Health Editor

Alkermes PLC ​has expanded into teh ​sleep⁣ disorder market⁤ with a definitive agreement to acquire Avadel Pharmaceuticals Inc. in a deal valued at $2.1‍ billion, the companies announced Monday. ‌The acquisition will add⁤ Avadel’s led product, Lopimpramine,​ a‍ once-nightly oral antidepressant in advancement for major⁢ depressive disorder, ‍to alkermes’ portfolio.

The deal represents Alkermes’ strategic entry into a⁣ new therapeutic ‍area, diversifying ⁣beyond its existing focus ‍on central nervous system disorders like schizophrenia and bipolar disorder. Avadel’s Lopimpramine, if approved by the Food and Drug Administration,‍ could offer a differentiated treatment option for the millions of Americans struggling with depression and sleep disturbances. The transaction is expected to⁤ close in the third quarter⁢ of⁤ 2024, subject ​to customary ​closing conditions, including regulatory approvals and Avadel shareholder approval.

Under the terms⁢ of the agreement, Alkermes will pay $15.50 per share in cash for ‍each Avadel share, representing a 36% premium to Avadel’s closing‌ share price on Friday. The ⁣combined company will leverage Alkermes’ commercial‌ infrastructure ⁤and expertise to maximize the potential of ‍Lopimpramine, targeting a launch⁤ in the frist⁣ half⁤ of⁢ 2025.

“This transaction ⁤is a compelling strategic fit for Alkermes,adding a promising late-stage ⁣development asset with notable commercial potential,” said Richard Lawfull,Executive Vice President and ‍Chief Commercial ​Officer of Alkermes. “Lopimpramine⁣ aligns well with our focus on addressing ⁣unmet‌ needs in neuroscience and complements our‌ existing portfolio.”

Avadel’s shares⁢ jumped more than 30% in premarket trading following the declaration, while Alkermes ⁤shares were down slightly. The ‍acquisition​ is ‌anticipated to be funded through a combination of ⁤cash on hand and debt financing.⁤

Alkermes has ‍a history ​of acquiring and developing ​innovative therapies, and this ‌move signals a continued commitment to growth and diversification ⁢within the pharmaceutical industry. The company’s existing portfolio includes ⁤products ‍for schizophrenia, bipolar⁣ I disorder, and alcohol dependence.

October 22, 2025 0 comments
0 FacebookTwitterPinterestEmail
Health

Alector Stock Plummets After Dementia Drug Trial Failure

by Dr. Michael Lee – Health Editor October 22, 2025
written by Dr. Michael Lee – Health Editor

Alector Inc. shares plummeted‍ over 60% on Monday after its lead drug candidate​ for early-stage Alzheimer’s disease failed to demonstrate ⁤a‍ statistically notable slowing ⁣of cognitive⁢ decline in a ‌late-stage clinical trial. The ‍disappointing results represent a major setback for the ⁢biotechnology⁤ company and a potential‍ blow to the field of Alzheimer’s‌ research, wich has seen numerous high-profile drug failures in recent years.

The ​Phase⁤ 3⁣ trial, known as Illuminate, evaluated Alector’s drug AL003 in 800 participants ⁣with mild cognitive impairment ‍due to Alzheimer’s disease. While the drug was found to be⁣ safe and well-tolerated, it did not ⁣meet its primary endpoint⁤ of improving cognitive function⁣ compared to a placebo⁢ group over ⁤18 months.The failure⁤ underscores ⁣the immense challenge of developing⁢ effective treatments for Alzheimer’s, a ​devastating neurodegenerative disease affecting ⁤over 6.7 million Americans, and highlights the urgent need for new⁢ therapeutic approaches.

Alector initiated ⁣a separate,ongoing⁣ trial called Transcend,evaluating AL003 in ​individuals with earlier stages ‍of Alzheimer’s disease,and⁤ plans to continue that study.Top-line⁤ data from Transcend is expected in‍ the ⁤first⁣ half of 2025. The company ⁢stated it​ is evaluating‌ the Illuminate data to understand potential reasons for the outcome and will present the full results at a future medical conference.

“We are deeply disappointed by these results,” said Dr. Arnon Rosenthal, CEO of Alector, in a press release. “We remain committed to our mission of developing innovative therapies for neurodegenerative diseases, and we will⁣ continue to advance our ⁢pipeline of programs.”

The stock closed at $8.48,⁤ down 63.8% from its Friday close of $18.62. The company’s market capitalization has fallen to approximately $450 million.

alzheimer’s disease⁣ is characterized by the accumulation of amyloid plaques and tau tangles‍ in the brain, ‍leading to⁢ neuronal damage and cognitive decline. Despite decades of research,there are ⁢currently limited treatment‍ options available,primarily focused on managing⁣ symptoms rather than slowing or halting disease progression. Recent approvals of drugs like Leqembi and‍ Aduhelm, ​which target amyloid plaques, have offered a glimmer of‍ hope, but thier clinical ‍benefits have been modest and accompanied by safety concerns.

October 22, 2025 0 comments
0 FacebookTwitterPinterestEmail
News

Trump, Merck KGaA announce deal to cut some IVF drug prices

by David Harrison – Chief Editor October 17, 2025
written by David Harrison – Chief Editor

WASHINGTON, Feb 29 – Former President Donald Trump adn⁤ Merck KGaA announced a⁢ deal ⁢Thursday too reduce the price of certain ​drugs‌ used in in-vitro fertilization ⁤(IVF), aiming to ease financial burdens for families‌ undergoing the costly treatment.

The agreement will lower the ⁤price of select fertility medications sold by Merck kgaas U.S. and Canadian ​affiliates by up ‌to 70%, benefiting⁤ an estimated one million Americans annually.⁣ Trump unveiled the initiative during ‌a⁣ campaign event in South ⁢Carolina, framing it as a victory for families and a commitment ⁤to supporting the creation of life. The price cuts ‌will be implemented throughout 2024, with some‌ reductions taking effect immediately.

“We’re making IVF more⁤ affordable⁤ and accessible for all,” Trump stated at the event. “This ⁤is a very critically important issue, and ⁢we’re going ⁣to ⁤continue to fight for families.”

The deal focuses on medications like ⁣Gonal-F, Menopur, and Cetrotide, essential for ovarian stimulation and‌ preventing premature ovulation during IVF cycles. The cost of ⁢a single IVF​ cycle can range from $12,000 to $15,000, with ⁣medication often accounting for 20-30% of the ‍total expense. Rising costs have increasingly limited access ​to IVF for many aspiring parents.

Merck KGaA, a German science and technology ‌company, stated ⁣the price reductions are part of its ongoing commitment⁢ to responsible pricing and patient access. “We are pleased to work with President ‌Trump to help‌ make⁤ fertility treatments more affordable for American families,” said a company spokesperson.

The announcement comes⁣ amid heightened political⁢ scrutiny of⁣ IVF access, especially‍ following a ‍recent Alabama Supreme Court ruling that⁢ raised concerns about ⁢the legal status of frozen embryos.The Trump campaign ‍has sought to capitalize on the ​issue, positioning the former president as a champion of family values and reproductive freedom.

October 17, 2025 0 comments
0 FacebookTwitterPinterestEmail
Health

FDA Approves Jazz Pharma and Roche Combination Therapy for Lung Cancer

by Dr. Michael Lee – Health Editor October 3, 2025
written by Dr. Michael Lee – Health Editor

Jazz Pharmaceuticals PLC​ said on Monday the U.S. Food ‍and Drug Governance approved Roche’s combination therapy of Tecentriq (atezolizumab) and⁢ Zybrestat (fosdenopterin) for adults with advanced non-small cell lung cancer whose tumors have EGFR exon 20 insertion ⁢mutations. The approval marks a significant advancement for⁢ patients with this specific,historically difficult-to-treat form‍ of lung cancer,offering a ⁤new targeted treatment option.

Approximately 5-10% ⁤of patients with non-small cell lung cancer harbor⁢ EGFR ‍exon‍ 20 ​insertion mutations. These mutations drive cancer growth but are ​not addressed by existing EGFR inhibitors. The ‌approval of the Tecentriq and​ Zybrestat combination, ⁣following a priority review, provides ⁣a much-needed therapy for this ⁢patient population, perhaps extending lives and‍ improving quality of​ life. The therapy’s approval‌ is based on ​data from​ the phase 3 MARIPOSA trial,⁤ which demonstrated a statistically significant ⁢enhancement in progression-free survival ​compared to chemotherapy.

The FDA granted ‍the combination therapy Breakthrough Therapy designation, Priority​ review, ⁢and Orphan Drug designation.The recommended dosage of Tecentriq⁣ is 1200 mg administered intravenously every three ​weeks, in combination with‍ Zybrestat, taken orally twice‍ daily. Jazz ⁢will co-promote the therapy with ‌Roche in the United States.

October 3, 2025 0 comments
0 FacebookTwitterPinterestEmail
Health

Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say

by Dr. Michael Lee – Health Editor October 2, 2025
written by Dr. Michael Lee – Health Editor

Novo Nordisk, Eli ⁣Lilly Weight-Loss Drugs Recommended as First-Line Obesity Treatments by European Doctors

LONDON, ⁤November 21, 2023 – Leading European doctors ​are advocating for a important shift in ‌obesity treatment‍ protocols, recommending that medications like ⁣Novo‍ NordiskS Wegovy and Eli Lilly‘s Mounjaro should be considered as ‍first-line options for ‌patients, rather than reserved for those who have failed to lose weight through diet and exercise alone. The‍ move signals ⁣a growing recognition of obesity⁢ as⁢ a chronic ​disease requiring medical intervention, similar to conditions⁤ like diabetes or hypertension.

For decades,lifestyle interventions have ⁤been the cornerstone of ⁣obesity management. Though, the limited long-term success rates of diet and exercise, coupled⁣ with⁣ the demonstrated efficacy of newer weight-loss drugs, are driving the⁢ call for ⁢a more aggressive and proactive approach. This shift coudl impact an estimated 50% of Europe’s adult population currently living with obesity, and ‌possibly ​alleviate the substantial ‍healthcare burden associated with related ​conditions like heart disease, type ​2 diabetes, and certain ⁢cancers.⁤

The proposal stems ‍from updated guidelines ⁣released this week by⁤ the⁢ European Association for the Study ‍of Obesity (EASO), reflecting a consensus among experts‍ that early pharmacological intervention can⁤ yield more substantial and‌ sustained weight ⁢loss, improving overall ​health outcomes.​ These drugs,known as GLP-1 receptor agonists,work by mimicking a natural hormone that regulates appetite and food intake.

“We are moving away from the idea ⁢that obesity is ‍a ‍matter⁢ of willpower,” explained Dr. Carel le Roux, EASO’s scientific advisor and professor of metabolic medicine at the University of Dublin, in⁤ a statement. “These medications are not a quick fix, but they‌ can ‌be a vrey effective tool when⁤ used in conjunction with lifestyle changes.”

Clinical trials​ have shown that Wegovy and Mounjaro can lead to weight losses of up to 20% of initial body weight, substantially exceeding the results⁣ typically achieved with ‌diet and exercise. While‍ potential side effects, such as ‌nausea and gastrointestinal discomfort, exist, doctors ⁢emphasize that the benefits often outweigh the risks for individuals with a body⁣ mass index (BMI) of 35 or higher, or those ‌with ⁢obesity-related health⁢ complications.

The updated guidelines ⁢also highlight the importance‌ of individualized⁢ treatment plans,considering factors such as patient preferences,co-existing medical conditions,and‍ potential drug interactions. Experts anticipate that wider‌ adoption‌ of these medications‌ as first-line treatments will ‍require‍ increased access, affordability, and ongoing monitoring to ensure patient ⁣safety and maximize effectiveness.

October 2, 2025 0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts

Search:

Recent Posts

  • Title: Ivory Chia Wins Asian Award for ‘Emerald Hill’ Performance

    December 5, 2025
  • Title: UBC Thunderbirds Golf: Successful Start to 2025-26 Season with New Leadership

    December 5, 2025
  • Letitia James: Grand Jury Rejects New Indictment – Legal Update

    December 5, 2025
  • Title: Bishop Blesses New Rectory at Naples Parish

    December 5, 2025
  • Cat Café Closed: Kitten Causes Flooding Damage in Richmond

    December 5, 2025

Follow Me

Follow Me
  • Live News Feeds
  • Short Important News
  • Most Important News
  • Headlinez
  • Most Recommended Web Hosting
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Copyright Notice
  • Disclaimer
  • DMCA Policy
  • EDITORIAL TEAM
  • Links
  • Privacy Policy
  • Terms & Conditions

@2025 - All Right Reserved.

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: contact@world-today-news.com


Back To Top
World Today News
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Technology
  • World
World Today News
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Technology
  • World
@2025 - All Right Reserved.

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: contact@world-today-news.com